These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28045934)

  • 41. Therapeutic review: tuberculosis.
    Houston S; Pozniak A; Ray CS
    Cent Afr J Med; 1991 Aug; 37(8):250-9. PubMed ID: 1807799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population-level impact of active tuberculosis case finding in an Asian megacity.
    Dowdy DW; Lotia I; Azman AS; Creswell J; Sahu S; Khan AJ
    PLoS One; 2013; 8(10):e77517. PubMed ID: 24147015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance.
    Van Deun A; Decroo T; Kya Jai Maug A; Hossain MA; Gumusboga M; Mulders W; Ortuño-Gutiérrez N; Lynen L; de Jong BC; Rieder HL
    PLoS One; 2020; 15(5):e0233500. PubMed ID: 32421749
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models.
    Pretorius C; Menzies NA; Chindelevitch L; Cohen T; Cori A; Eaton JW; Fraser C; Gopalappa C; Hallett TB; Salomon JA; Stover J; White RG; Dodd PJ
    AIDS; 2014 Jan; 28 Suppl 1():S25-34. PubMed ID: 24468944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan.
    Lin YJ; Lin HC; Yang YF; Chen CY; Lu TH; Liao CM
    Int J Infect Dis; 2020 Aug; 97():135-142. PubMed ID: 32474203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.
    Abu-Raddad LJ; Sabatelli L; Achterberg JT; Sugimoto JD; Longini IM; Dye C; Halloran ME
    Proc Natl Acad Sci U S A; 2009 Aug; 106(33):13980-5. PubMed ID: 19666590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.
    Sachdeva KS; Raizada N; Gupta RS; Nair SA; Denkinger C; Paramasivan CN; Kulsange S; Thakur R; Dewan P; Boehme C; Arinaminpathy N
    PLoS One; 2015; 10(7):e0131438. PubMed ID: 26132584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?
    Ndjeka N; Hughes J; Reuter A; Conradie F; Enwerem M; Ferreira H; Ismail N; Kock Y; Master I; Meintjes G; Padanilam X; Romero R; Schaaf HS; Riele JT; Maartens G
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1073-1080. PubMed ID: 33126942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
    Ruan Q; Liu Q; Sun F; Shao L; Jin J; Yu S; Ai J; Zhang B; Zhang W
    Emerg Microbes Infect; 2016 Feb; 5(2):e12. PubMed ID: 26905025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
    Trauer JM; Achar J; Parpieva N; Khamraev A; Denholm JT; Falzon D; Jaramillo E; Mesic A; du Cros P; McBryde ES
    BMC Med; 2016 Nov; 14(1):187. PubMed ID: 27855693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tuberculosis and malnutrition: The European perspective.
    Ockenga J; Fuhse K; Chatterjee S; Malykh R; Rippin H; Pirlich M; Yedilbayev A; Wickramasinghe K; Barazzoni R
    Clin Nutr; 2023 Apr; 42(4):486-492. PubMed ID: 36857957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis.
    Dowdy DW; Basu S; Andrews JR
    Am J Respir Crit Care Med; 2013 Mar; 187(5):543-51. PubMed ID: 23262515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models.
    Houben RMGJ; Menzies NA; Sumner T; Huynh GH; Arinaminpathy N; Goldhaber-Fiebert JD; Lin HH; Wu CY; Mandal S; Pandey S; Suen SC; Bendavid E; Azman AS; Dowdy DW; Bacaër N; Rhines AS; Feldman MW; Handel A; Whalen CC; Chang ST; Wagner BG; Eckhoff PA; Trauer JM; Denholm JT; McBryde ES; Cohen T; Salomon JA; Pretorius C; Lalli M; Eaton JW; Boccia D; Hosseini M; Gomez GB; Sahu S; Daniels C; Ditiu L; Chin DP; Wang L; Chadha VK; Rade K; Dewan P; Hippner P; Charalambous S; Grant AD; Churchyard G; Pillay Y; Mametja LD; Kimerling ME; Vassall A; White RG
    Lancet Glob Health; 2016 Nov; 4(11):e806-e815. PubMed ID: 27720688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.
    Sweeney S; Berry C; Kazounis E; Motta I; Vassall A; Dodd M; Fielding K; Nyang'wa BT
    PLOS Glob Public Health; 2022; 2(12):e0001337. PubMed ID: 36962909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.